About RocheWe have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Founder: Fritz Hoffmann-La Roche
CEO: Severin Schwan
CFO: Alan Hippe
Please click here for clinical trial information..
US Product Portfolio.
For more information, visit www.roche.com and follow us on www.twitter.com/Roche.
Tweets by Roche
1510 articles with Roche
The trial demonstrated equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.
According to news reports, a six-year-old girl in North Texas was provided Tamiflu and had a rare reaction that affected her nervous system.
In the deal, both companies will leverage their respective platforms, including MacroGenics’ DART platform and Roche’s CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.
TECENTRIQ and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1.
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
Genentech is claiming that Pfizer's proposed biosimilar infringes 40 of its patents.
Under the deal, Roche is acquiring all shares of the company.
Genentech scored two approvals from the FDA this week.
11/16/2017The drug will be used to prevent or reduce the frequency of bleeding episodes in certain patients.
The companies are ranked by revenues of clinical diagnostic test instruments, reagents and supplies.
10/26/2017Here is how you can land a job at one of the biggest pharmaceuticals in the world.
The lawsuit was filed on behalf of members of the American military who were injured or killed by attacks between 2005 and 2009
Inovio Pharmaceuticals Begins Phase Ib/II Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
Inovio announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab in combination with Inovio’s INO-5401 and INO-9012.
Roche To Initiate Testing For Babesia Parasite At U.S. Blood Centers Under FDA Investigational New Drug Application Protocol
Roche Gains CE Label Expansion For PD-L1 Testing In Lung And Bladder Cancers In Markets Where TECENTRIQ Is Approved
Halozyme's Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.